RNTX
Rein Therapeutics Inc.
Medical - Pharmaceuticals
Market Cap$22K
5Y Perf.-47.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
RNTX vs ATXI
Revenue, margins, valuation, and 5-year total return — side by side.
ATXI
Avenue Therapeutics, Inc.
Biotechnology
Market Cap$2M
5Y Perf.-73.5%
RNTX vs ATXI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RNTX | ATXI |
|---|---|---|
| Industry | Medical - Pharmaceuticals | Biotechnology |
| Market Cap | $22K | $2M |
| Revenue (TTM) | $0.00 | $1M |
| Net Income (TTM) | $-59M | $-4M |
| Gross Margin | — | 100.0% |
| Operating Margin | — | -279.8% |
| Total Debt | $0.00 | $0.00 |
| Cash & Equiv. | $13M | $3M |
RNTX vs ATXI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RNTX
ATXI
| Stock | Dec 24 | May 26 | Return |
|---|---|---|---|
| Rein Therapeutics I… (RNTX) | 100 | 53.0 | -47.0% |
| Avenue Therapeutics… (ATXI) | 100 | 26.5 | -73.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RNTX vs ATXI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RNTX and ATXI are tied at the top with 2 categories each — the right choice depends on your priorities. Avenue Therapeutics, Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
RNTX
Rein Therapeutics Inc.
The Long-Run Compounder
RNTX has the current edge in this matchup, primarily because of its strength in long-term compounding.
- -42.5% 10Y total return vs ATXI's -100.0%
- 16.7% revenue growth vs ATXI's -30.5%
- 0.6% margin vs ATXI's -266.7%
Best for: long-term compounding
ATXI
Avenue Therapeutics, Inc.
The Growth Play
ATXI is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- EPS growth 98.8%
- Lower volatility, beta -0.23, current ratio 3.27x
- Beta -0.23, current ratio 3.27x
Best for: growth exposure and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RNTX | 16.7% revenue growth vs ATXI's -30.5% |
| Quality / Margins | RNTX | 0.6% margin vs ATXI's -266.7% |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ATXI | +140.8% vs RNTX's -29.1% |
| Efficiency (ROA) | ATXI | -105.8% ROA vs RNTX's -109.6% |
RNTX vs ATXI — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRNTXLAGGINGATXI
ATXIAvenue Therapeutics, …
2leads
RNTXRein Therapeutics Inc.
2leads
6 Total Categories
CATEGORYLEADERvs ATXIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ATXI1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
RNTX3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
RNTX5/6
Risk & VolatilityBeta, volatility, and downside exposure
ATXI2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ATXI leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ATXI and RNTX operate at a comparable scale, with $1M and $0 in trailing revenue.
| Metric | RNTXRein Therapeutics… | ATXIAvenue Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $1M |
| EBITDAEarnings before interest/tax | -$61M | -$4M |
| Net IncomeAfter-tax profit | -$59M | -$4M |
| Free Cash FlowCash after capex | -$21M | -$2M |
| Gross MarginGross profit ÷ Revenue | — | +100.0% |
| Operating MarginEBIT ÷ Revenue | — | -2.8% |
| Net MarginNet income ÷ Revenue | — | -2.7% |
| FCF MarginFCF ÷ Revenue | — | -124.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +22.2% | +89.1% |
ATXI leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — RNTX and ATXI each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | RNTXRein Therapeutics… | ATXIAvenue Therapeuti… |
|---|---|---|
| Market CapShares × price | $21,884 | $2M |
| Enterprise ValueMkt cap + debt − cash | -$13M | -$906,784 |
| Trailing P/EPrice ÷ TTM EPS | -0.35x | -0.59x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.00x | 3.70x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — RNTX and ATXI each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
RNTX leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
RNTX delivers a -127.5% return on equity — every $100 of shareholder capital generates $-127 in annual profit, vs $-161 for ATXI. On the Piotroski fundamental quality scale (0–9), ATXI scores 2/9 vs RNTX's 1/9, reflecting mixed financial health.
| Metric | RNTXRein Therapeutics… | ATXIAvenue Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | -127.5% | -160.6% |
| ROA (TTM)Return on assets | -109.6% | -105.8% |
| ROICReturn on invested capital | -3.1% | — |
| ROCEReturn on capital employed | -78.9% | -9.0% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 2 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | -$13M | -$3M |
| Cash & Equiv.Liquid assets | $13M | $3M |
| Total DebtShort + long-term debt | $0 | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
RNTX leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
RNTX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RNTX five years ago would be worth $5,755 today (with dividends reinvested), compared to $1 for ATXI. Over the past 12 months, ATXI leads with a +140.8% total return vs RNTX's -29.1%. The 3-year compound annual growth rate (CAGR) favors RNTX at -16.8% vs ATXI's -80.9% — a key indicator of consistent wealth creation.
| Metric | RNTXRein Therapeutics… | ATXIAvenue Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | -2.4% | -22.7% |
| 1-Year ReturnPast 12 months | -29.1% | +140.8% |
| 3-Year ReturnCumulative with dividends | -42.5% | -99.3% |
| 5-Year ReturnCumulative with dividends | -42.5% | -100.0% |
| 10-Year ReturnCumulative with dividends | -42.5% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -16.8% | -80.9% |
RNTX leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
ATXI leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ATXI is the less volatile stock with a -0.23 beta — it tends to amplify market swings less than RNTX's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ATXI currently trades 54.6% from its 52-week high vs RNTX's 50.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RNTXRein Therapeutics… | ATXIAvenue Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.37x | -0.23x |
| 52-Week HighHighest price in past year | $2.40 | $0.97 |
| 52-Week LowLowest price in past year | $1.00 | $0.15 |
| % of 52W HighCurrent price vs 52-week peak | +50.8% | +54.6% |
| RSI (14)Momentum oscillator 0–100 | 40.0 | 54.6 |
| Avg Volume (50D)Average daily shares traded | 582K | 3K |
ATXI leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | RNTXRein Therapeutics… | ATXIAvenue Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ATXI leads in 2 of 6 categories (Income & Cash Flow, Risk & Volatility). RNTX leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Best OverallRein Therapeutics Inc. (RNTX)Leads 2 of 6 categories
Loading custom metrics...
RNTX vs ATXI: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — RNTX or ATXI?
Over the past 5 years, Rein Therapeutics Inc.
(RNTX) delivered a total return of -42. 5%, compared to -100. 0% for Avenue Therapeutics, Inc. (ATXI). Over 10 years, the gap is even starker: RNTX returned -42. 5% versus ATXI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — RNTX or ATXI?
By beta (market sensitivity over 5 years), Avenue Therapeutics, Inc.
(ATXI) is the lower-risk stock at -0. 23β versus Rein Therapeutics Inc. 's 1. 37β — meaning RNTX is approximately -694% more volatile than ATXI relative to the S&P 500.
03Which is growing faster — RNTX or ATXI?
On earnings-per-share growth, the picture is similar: Avenue Therapeutics, Inc.
grew EPS 98. 8% year-over-year, compared to -2. 6% for Rein Therapeutics Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — RNTX or ATXI?
Rein Therapeutics Inc.
(RNTX) is the more profitable company, earning 0. 0% net margin versus -266. 7% for Avenue Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNTX leads at 0. 0% versus -279. 8% for ATXI. At the gross margin level — before operating expenses — ATXI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — RNTX or ATXI?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is RNTX or ATXI better for a retirement portfolio?
For long-horizon retirement investors, Avenue Therapeutics, Inc.
(ATXI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 23)). Both have compounded well over 10 years (ATXI: -100. 0%, RNTX: -42. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between RNTX and ATXI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.